FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073169852> ?p ?o ?g. }

• W2073169852 endingPage "618" @default.
• W2073169852 startingPage "613" @default.
• W2073169852 abstract "Several cytotoxic chemotherapy regimens are active against metastatic breast cancer; however, benefits are modest and overall prognosis remains limited. For anthracycline and taxane-pretreated metastatic breast cancer, there remains a relative paucity of therapies with significant activity. This Phase II study evaluated the combination of capecitabine and oxaliplatin (XELOX) among patients with metastatic breast cancer being treated in the first- or second-line setting.Patients received oxaliplatin 85 mg/m(2) on days 1 and 15, and capecitabine 1,500 mg/m(2) twice daily on days 1-7 and 15-21 of a 28-day cycle. Patients were treated until progression or intolerable toxicity. The primary objective was to estimate the objective response rate by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria with tumor assessments every 8 weeks.Ten patients were treated of which 3 had received prior neurotoxic therapy in the metastatic setting. There were no confirmed complete responses, 5 patients had partial response, 4 patients had stable disease for at least 24 weeks, and one patient was unevaluable. Median time to progression (TTP) was 10.4 months (95% lower confidence bound [LCB]: 5.75 months), median progression-free survival (PFS) was 14.2 months (95% LCB: 6.14 months), and median overall survival (OS) was 19 months (95% LCB: 12.8 months). Multiple patients experienced pain syndromes and unusual neuropathies. Other common toxicities included fatigue, diarrhea, and nausea.XELOX is a promising regimen for anthracycline-pretreated metastatic breast cancer although careful patient selection is indicated and alternate dosing schedules should be explored to minimize neurologic morbidity." @default.
• W2073169852 created "2016-06-24" @default.
• W2073169852 creator A5002970130 @default.
• W2073169852 creator A5006396363 @default.
• W2073169852 creator A5010228005 @default.
• W2073169852 creator A5011216248 @default.
• W2073169852 creator A5013521413 @default.
• W2073169852 creator A5031465905 @default.
• W2073169852 creator A5041442103 @default.
• W2073169852 creator A5050896891 @default.
• W2073169852 creator A5074281121 @default.
• W2073169852 creator A5082901504 @default.
• W2073169852 creator A5084695166 @default.
• W2073169852 date "2012-12-11" @default.
• W2073169852 modified "2023-10-16" @default.
• W2073169852 title "Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial" @default.
• W2073169852 cites W1939003096 @default.
• W2073169852 cites W1972248724 @default.
• W2073169852 cites W2007304396 @default.
• W2073169852 cites W2032553799 @default.
• W2073169852 cites W2039310969 @default.
• W2073169852 cites W2058453858 @default.
• W2073169852 cites W2065982243 @default.
• W2073169852 cites W2078270553 @default.
• W2073169852 cites W2099658604 @default.
• W2073169852 cites W2113919377 @default.
• W2073169852 cites W2119541084 @default.
• W2073169852 cites W2124410855 @default.
• W2073169852 cites W2139248078 @default.
• W2073169852 cites W2139687160 @default.
• W2073169852 cites W2148415679 @default.
• W2073169852 cites W2150296977 @default.
• W2073169852 cites W2165782026 @default.
• W2073169852 cites W2171684168 @default.
• W2073169852 cites W2219209903 @default.
• W2073169852 cites W2917423152 @default.
• W2073169852 doi "https://doi.org/10.1007/s00280-012-2044-2" @default.
• W2073169852 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3581759" @default.
• W2073169852 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23228989" @default.
• W2073169852 hasPublicationYear "2012" @default.
• W2073169852 type Work @default.
• W2073169852 sameAs 2073169852 @default.
• W2073169852 citedByCount "8" @default.
• W2073169852 countsByYear W20731698522013 @default.
• W2073169852 countsByYear W20731698522014 @default.
• W2073169852 countsByYear W20731698522015 @default.
• W2073169852 countsByYear W20731698522017 @default.
• W2073169852 countsByYear W20731698522018 @default.
• W2073169852 countsByYear W20731698522019 @default.
• W2073169852 countsByYear W20731698522021 @default.
• W2073169852 crossrefType "journal-article" @default.
• W2073169852 hasAuthorship W2073169852A5002970130 @default.
• W2073169852 hasAuthorship W2073169852A5006396363 @default.
• W2073169852 hasAuthorship W2073169852A5010228005 @default.
• W2073169852 hasAuthorship W2073169852A5011216248 @default.
• W2073169852 hasAuthorship W2073169852A5013521413 @default.
• W2073169852 hasAuthorship W2073169852A5031465905 @default.
• W2073169852 hasAuthorship W2073169852A5041442103 @default.
• W2073169852 hasAuthorship W2073169852A5050896891 @default.
• W2073169852 hasAuthorship W2073169852A5074281121 @default.
• W2073169852 hasAuthorship W2073169852A5082901504 @default.
• W2073169852 hasAuthorship W2073169852A5084695166 @default.
• W2073169852 hasBestOaLocation W20731698522 @default.
• W2073169852 hasConcept C121608353 @default.
• W2073169852 hasConcept C126322002 @default.
• W2073169852 hasConcept C141071460 @default.
• W2073169852 hasConcept C143998085 @default.
• W2073169852 hasConcept C2775930923 @default.
• W2073169852 hasConcept C2776694085 @default.
• W2073169852 hasConcept C2776802502 @default.
• W2073169852 hasConcept C2777511904 @default.
• W2073169852 hasConcept C2777909004 @default.
• W2073169852 hasConcept C2778336483 @default.
• W2073169852 hasConcept C2778822529 @default.
• W2073169852 hasConcept C2779984678 @default.
• W2073169852 hasConcept C2780580376 @default.
• W2073169852 hasConcept C2780739268 @default.
• W2073169852 hasConcept C2780962732 @default.
• W2073169852 hasConcept C2781413609 @default.
• W2073169852 hasConcept C526805850 @default.
• W2073169852 hasConcept C530470458 @default.
• W2073169852 hasConcept C71924100 @default.
• W2073169852 hasConceptScore W2073169852C121608353 @default.
• W2073169852 hasConceptScore W2073169852C126322002 @default.
• W2073169852 hasConceptScore W2073169852C141071460 @default.
• W2073169852 hasConceptScore W2073169852C143998085 @default.
• W2073169852 hasConceptScore W2073169852C2775930923 @default.
• W2073169852 hasConceptScore W2073169852C2776694085 @default.
• W2073169852 hasConceptScore W2073169852C2776802502 @default.
• W2073169852 hasConceptScore W2073169852C2777511904 @default.
• W2073169852 hasConceptScore W2073169852C2777909004 @default.
• W2073169852 hasConceptScore W2073169852C2778336483 @default.
• W2073169852 hasConceptScore W2073169852C2778822529 @default.
• W2073169852 hasConceptScore W2073169852C2779984678 @default.
• W2073169852 hasConceptScore W2073169852C2780580376 @default.
• W2073169852 hasConceptScore W2073169852C2780739268 @default.
• W2073169852 hasConceptScore W2073169852C2780962732 @default.
• W2073169852 hasConceptScore W2073169852C2781413609 @default.

• next